An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
10 2022
Historique:
received: 24 07 2021
revised: 02 09 2021
accepted: 10 09 2021
pubmed: 9 10 2021
medline: 28 9 2022
entrez: 8 10 2021
Statut: ppublish

Résumé

Gastric cancer (GC) remains a leading cause of mortality among certain racial, ethnic, and immigrant groups in the United States (US). The majority of GCs are diagnosed at advanced stages, and overall survival remains poor. There exist no structured national strategies for GC prevention in the US. On March 5-6, 2020 a summit of researchers, policy makers, public funders, and advocacy leaders was convened at Stanford University to address this critical healthcare disparity. After this summit, a writing group was formed to critically evaluate the effectiveness, potential benefits, and potential harms of methods of primary and secondary prevention through structured literature review. This article represents a consensus statement prepared by the writing group. The burden of GC is highly inequitably distributed in the US and disproportionately falls on Asian, African American, Hispanic, and American Indian/Alaskan Native populations. In randomized controlled trials, strategies of Helicobacter pylori testing and treatment have been demonstrated to reduce GC-specific mortality. In well-conducted observational and ecologic studies, strategies of endoscopic screening have been associated with reduced GC-specific mortality. Notably however, all randomized controlled trial data (for primary prevention) and the majority of observational data (for secondary prevention) are derived from non-US sources. There exist substantial, high-quality data supporting GC prevention derived from international studies. There is an urgent need for cancer prevention trials focused on high-risk immigrant and minority populations in the US. The authors offer recommendations on how strategies of primary and secondary prevention can be applied to the heterogeneous US population.

Sections du résumé

BACKGROUND & AIMS
Gastric cancer (GC) remains a leading cause of mortality among certain racial, ethnic, and immigrant groups in the United States (US). The majority of GCs are diagnosed at advanced stages, and overall survival remains poor. There exist no structured national strategies for GC prevention in the US.
METHODS
On March 5-6, 2020 a summit of researchers, policy makers, public funders, and advocacy leaders was convened at Stanford University to address this critical healthcare disparity. After this summit, a writing group was formed to critically evaluate the effectiveness, potential benefits, and potential harms of methods of primary and secondary prevention through structured literature review. This article represents a consensus statement prepared by the writing group.
RESULTS
The burden of GC is highly inequitably distributed in the US and disproportionately falls on Asian, African American, Hispanic, and American Indian/Alaskan Native populations. In randomized controlled trials, strategies of Helicobacter pylori testing and treatment have been demonstrated to reduce GC-specific mortality. In well-conducted observational and ecologic studies, strategies of endoscopic screening have been associated with reduced GC-specific mortality. Notably however, all randomized controlled trial data (for primary prevention) and the majority of observational data (for secondary prevention) are derived from non-US sources.
CONCLUSIONS
There exist substantial, high-quality data supporting GC prevention derived from international studies. There is an urgent need for cancer prevention trials focused on high-risk immigrant and minority populations in the US. The authors offer recommendations on how strategies of primary and secondary prevention can be applied to the heterogeneous US population.

Identifiants

pubmed: 34624563
pii: S1542-3565(21)01054-5
doi: 10.1016/j.cgh.2021.09.039
pmc: PMC8983795
mid: NIHMS1775857
pii:
doi:

Types de publication

Journal Article Review Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2218-2228.e2

Subventions

Organisme : CSRD VA
ID : IK2 CX002027
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA252635
Pays : United States
Organisme : AHRQ HHS
ID : K12 HS026395
Pays : United States
Organisme : NCI NIH HHS
ID : R44 CA180425
Pays : United States

Informations de copyright

Copyright © 2022 AGA Institute. All rights reserved.

Auteurs

Robert J Huang (RJ)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, California.

Meira Epplein (M)

Department of Population Health Sciences, Duke University, and Cancer Risk, Detection, and Interception Program, Duke Cancer Institute, Durham, North Carolina.

Chisato Hamashima (C)

Faculty of Medical Technology, Teikyo University, Tokyo, Japan.

Il Ju Choi (IJ)

Center for Gastric Cancer, National Cancer Center, Goyang, South Korea.

Eunjung Lee (E)

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Dennis Deapen (D)

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Yanghee Woo (Y)

Division of Surgical Oncology, Department of Surgery, City of Hope National Comprehensive Cancer Center, Duarte, California.

Thuy Tran (T)

Division of Surgical Oncology, Department of Surgery, City of Hope National Comprehensive Cancer Center, Duarte, California.

Shailja C Shah (SC)

Gastroenterology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California; Division of Gastroenterology and Moores Cancer Center, University of California, San Diego, La Jolla, California.

John M Inadomi (JM)

Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

David A Greenwald (DA)

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Joo Ha Hwang (JH)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, California. Electronic address: jooha@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH